{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "LINE1",
      "SARS-CoV-2",
      "chimeric RNAs",
      "genomic integration",
      "reverse transcription"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33958444",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "13"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "11",
    "Day": "12"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e2105968118",
      "10.1073/pnas.2105968118"
    ],
    "Journal": {
      "ISSN": "1091-6490",
      "JournalIssue": {
        "Volume": "118",
        "Issue": "21",
        "PubDate": {
          "Year": "2021",
          "Month": "May",
          "Day": "25"
        }
      },
      "Title": "Proceedings of the National Academy of Sciences of the United States of America",
      "ISOAbbreviation": "Proc Natl Acad Sci U S A"
    },
    "ArticleTitle": "Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues.",
    "Abstract": {
      "AbstractText": [
        "Prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and recurrence of PCR-positive tests have been widely reported in patients after recovery from COVID-19, but some of these patients do not appear to shed infectious virus. We investigated the possibility that SARS-CoV-2 RNAs can be reverse-transcribed and integrated into the DNA of human cells in culture and that transcription of the integrated sequences might account for some of the positive PCR tests seen in patients. In support of this hypothesis, we found that DNA copies of SARS-CoV-2 sequences can be integrated into the genome of infected human cells. We found target site duplications flanking the viral sequences and consensus LINE1 endonuclease recognition sequences at the integration sites, consistent with a LINE1 retrotransposon-mediated, target-primed reverse transcription and retroposition mechanism. We also found, in some patient-derived tissues, evidence suggesting that a large fraction of the viral sequences is transcribed from integrated DNA copies of viral sequences, generating viral-host chimeric transcripts. The integration and transcription of viral sequences may thus contribute to the detection of viral RNA by PCR in patients after infection and clinical recovery. Because we have detected only subgenomic sequences derived mainly from the 3' end of the viral genome integrated into the DNA of the host cell, infectious virus cannot be produced from the integrated subgenomic SARS-CoV-2 sequences."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 the Author(s). Published by PNAS."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          }
        ],
        "LastName": "Zhang",
        "ForeName": "Liguo",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          }
        ],
        "LastName": "Richards",
        "ForeName": "Alexsia",
        "Initials": "A"
      },
      {
        "Identifier": [
          "0000-0003-3393-4814"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          }
        ],
        "LastName": "Barrasa",
        "ForeName": "M Inmaculada",
        "Initials": "MI"
      },
      {
        "Identifier": [
          "0000-0002-9176-4377"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702."
          }
        ],
        "LastName": "Hughes",
        "ForeName": "Stephen H",
        "Initials": "SH"
      },
      {
        "Identifier": [
          "0000-0001-8855-8647"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142."
          }
        ],
        "LastName": "Young",
        "ForeName": "Richard A",
        "Initials": "RA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142; jaenisch@wi.mit.edu."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142."
          }
        ],
        "LastName": "Jaenisch",
        "ForeName": "Rudolf",
        "Initials": "R"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 MH104610",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "1U19AI131135-01",
        "Acronym": "NH",
        "Agency": "NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "U19 AI131135",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "5R01MH104610-21",
        "Acronym": "NH",
        "Agency": "NIH HHS",
        "Country": "United States"
      },
      {
        "Acronym": "ImNIH",
        "Agency": "Intramural NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, N.I.H., Intramural",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Proc Natl Acad Sci U S A",
    "NlmUniqueID": "7505876",
    "ISSNLinking": "0027-8424"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Viral"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "Proc Natl Acad Sci U S A. 2021 Aug 17;118(33):",
      "PMID": "34344759"
    },
    {
      "RefSource": "Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):",
      "PMID": "34702741"
    },
    {
      "RefSource": "Retrovirology. 2021 Oct 29;18(1):34",
      "PMID": "34715873"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chlorocebus aethiops"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genome, Viral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "HEK293 Cells"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "RNA, Viral"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vero Cells"
    },
    {
      "QualifierName": [
        "genetics",
        "physiology"
      ],
      "DescriptorName": "Virus Integration"
    },
    {
      "QualifierName": [
        "genetics",
        "physiology"
      ],
      "DescriptorName": "Virus Replication"
    }
  ],
  "CoiStatement": "Competing interest statement: R.J. is an advisor/co-founder of Fate Therapeutics, Fulcrum Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics. R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics."
}